|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0030705,
umls-concept:C0086960,
umls-concept:C0087111,
umls-concept:C0178602,
umls-concept:C0221102,
umls-concept:C0332174,
umls-concept:C0574032,
umls-concept:C0600688,
umls-concept:C2931822
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1996-7-8
|
|
pubmed:abstractText |
Cisplatin, 5-flourouracil (5-FU), and leucovorin (PFL) chemotherapy has been reported to be effective in the treatment of cancers but severe mucositis or neutropenia are dose limiting toxicities. This Phase II study evaluated the anticancer effect and the toxicities of a new weekly 24-hour infusional PFL chemotherapy in patients with nasopharyngeal carcinoma (NPC).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2186-92
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8635020-Adult,
pubmed-meshheading:8635020-Aged,
pubmed-meshheading:8635020-Ambulatory Care,
pubmed-meshheading:8635020-Antidotes,
pubmed-meshheading:8635020-Antimetabolites, Antineoplastic,
pubmed-meshheading:8635020-Antineoplastic Agents,
pubmed-meshheading:8635020-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8635020-Carcinoma,
pubmed-meshheading:8635020-Cisplatin,
pubmed-meshheading:8635020-Dose-Response Relationship, Drug,
pubmed-meshheading:8635020-Drug Administration Schedule,
pubmed-meshheading:8635020-Female,
pubmed-meshheading:8635020-Fluorouracil,
pubmed-meshheading:8635020-Humans,
pubmed-meshheading:8635020-Infusions, Intravenous,
pubmed-meshheading:8635020-Leucovorin,
pubmed-meshheading:8635020-Male,
pubmed-meshheading:8635020-Middle Aged,
pubmed-meshheading:8635020-Nasopharyngeal Neoplasms,
pubmed-meshheading:8635020-Neoplasm Recurrence, Local,
pubmed-meshheading:8635020-Neutropenia,
pubmed-meshheading:8635020-Remission Induction,
pubmed-meshheading:8635020-Stomatitis,
pubmed-meshheading:8635020-Survival Rate
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
|
|
pubmed:affiliation |
Cancer Therapy Center, Veterans General Hospital-Taipei, Taiwan, Taipei, Republic of China.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
